Phathom Pharmaceuticals Inc [PHAT] stock is trading at $12.53, up 6.01%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PHAT shares have gain 7.92% over the last week, with a monthly amount glided 5.83%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Phathom Pharmaceuticals Inc [NASDAQ: PHAT] stock has seen the most recent analyst activity on February 14, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $23. Previously, Stifel started tracking the stock with Buy rating on May 03, 2024, and set its price target to $24. On January 05, 2024, Needham reiterated its Buy rating and revised its price target to $26 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $28 on August 09, 2023. Evercore ISI upgraded its rating to a Outperform. Craig Hallum started tracking with a Buy rating for this stock on March 13, 2023, and assigned it a price target of $21. In a note dated October 21, 2022, Jefferies initiated an Buy rating and provided a target price of $16 on this stock.
Phathom Pharmaceuticals Inc [PHAT] stock has fluctuated between $2.21 and $19.50 over the past year. Currently, Wall Street analysts expect the stock to reach $23.83 within the next 12 months. Phathom Pharmaceuticals Inc [NASDAQ: PHAT] shares were valued at $12.53 at the most recent close of the market. An investor can expect a potential return of 90.18% based on the average PHAT price forecast.
Analyzing the PHAT fundamentals
Phathom Pharmaceuticals Inc [NASDAQ:PHAT] reported sales of 114.04M for the trailing twelve months, which represents a growth of 439.36%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -2.36%, Pretax Profit Margin comes in at -2.9%, and Net Profit Margin reading is -2.9%. To continue investigating profitability, this company’s Return on Assets is posted at -1.32, Equity is 1.11 and Total Capital is -1.7. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.42.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Phathom Pharmaceuticals Inc’s Current Ratio is 2.38. Further, the Quick Ratio stands at 2.35, while the Cash Ratio is 1.63. Considering the valuation of this stock, the price to sales ratio is 7.79.
Transactions by insiders
Recent insider trading involved Breedlove Robert Charles, Principal Accounting Officer, that happened on Sep 05 ’25 when 461.0 shares were sold. Principal Accounting Officer, Breedlove Robert Charles completed a deal on Jul 16 ’25 to sell 1692.0 shares. Meanwhile, Director Topper James N bought 3780.0 shares on May 21 ’25.
